Home
/
Ensysce Biosciences, Inc.
/
Financials
/
Quarterly
Ensysce Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Ensysce Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$493.1K
Nov 14, 2025
Q2
2025
Jun 30, 2025
$1.37M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$1.32M
May 13, 2025
Q3
2025
Sep 30, 2024
$3.42M
Nov 14, 2025
Q2
2025
Jun 30, 2024
$181.8K
Aug 13, 2025
Q1
2025
Mar 31, 2024
$305.7K
May 13, 2025
Q3
2024
Sep 30, 2023
$435.4K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$490.5K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$789.6K
May 13, 2024
Q3
2023
Sep 30, 2022
$279.4K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$207.5K
Aug 11, 2023
Q1
2023
Mar 31, 2022
$603.1K
May 15, 2023
Q3
2022
Sep 30, 2021
$1.20M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$444.5K
Aug 11, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Sep 30, 2021
($17.16M)
Nov 15, 2021
Q2
2021
Jun 30, 2021
($935.5K)
Aug 16, 2021
Q1
2021
Mar 31, 2021
($1.71M)
Jun 8, 2021
Q3
2021
Sep 30, 2020
$1.57M
Nov 15, 2021
Q3
2020
Jun 30, 2020
$2.61M
Nov 9, 2020
Q2
2021
Jun 30, 2020
($704.5K)
Aug 16, 2021
Q1
2021
Mar 31, 2020
$1.79M
Jun 8, 2021
Q3
2020
Mar 31, 2020
($349.9K)
Nov 9, 2020
Q2
2020
Mar 31, 2020
($349.9K)
Aug 7, 2020
Q3
2020
Sep 30, 2019
$489.7K
Nov 9, 2020
Q3
2020
Jun 30, 2019
$418.9K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$418.9K
Aug 7, 2020
Q1
2020
Mar 31, 2019
$775.9K
May 7, 2020
Q2
2020
Mar 31, 2019
$775.9K
Aug 7, 2020
Q3
2020
Mar 31, 2019
$775.9K
Nov 9, 2020
Q3
2019
Sep 30, 2018
$577.6K
Nov 7, 2019
Q3
2019
Jun 30, 2018
$415.1K
Nov 7, 2019
Q2
2019
Jun 30, 2018
$415.1K
Aug 7, 2019
Q2
2019
Mar 31, 2018
$406.1K
Aug 7, 2019
Q3
2019
Mar 31, 2018
$406.1K
Nov 7, 2019
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.74M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($1.75M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($1.97M)
May 13, 2025
Q3
2025
Sep 30, 2024
$644.7K
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.96M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($1.84M)
May 13, 2025
Q3
2024
Sep 30, 2023
($2.71M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($2.29M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($2.56M)
May 13, 2024
Q3
2023
Sep 30, 2022
($6.16M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($7.06M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($4.80M)
May 15, 2023
Q3
2022
Sep 30, 2021
($16.89M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($412.6K)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($524.3K)
May 12, 2022
Q3
2021
Sep 30, 2020
($404.8K)
Nov 15, 2021
Q2
2021
Jun 30, 2020
$139.1K
Aug 16, 2021
Q1
2021
Mar 31, 2020
($915.2K)
Jun 8, 2021
Q3
2020
Sep 30, 2019
($584.4K)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($625.9K)
Aug 7, 2020